Organon & Co. OGN
Set alert
As of Nov 2, 12:31 PM ET
- YTD
- +92.82%
- 1 year
- +104.81%
- Open
- 13.85
- Prev close
- 13.84
- Mkt cap
- 3.63B
- Vol
- 686.20K
- Avg vol
- 2.58M
- EPS
- 0.78
- P/E
- 17.72
- Div yield
- 0.58%
More statistics
- Low
- 13.82
- High
- 13.84
- Forward P/E
- 3.79
- Beta
- 1.54
- Short ratio
- 8.54
- Inst. own
- 84.60%
- Dividend
- 0.08
- Ex-div date
- Aug 13, 2026
- Earnings
- Feb 11, 2027
- 50-d avg
- 13.74
- 200-d avg
- 11.49
- 1y target
- 10.33
5Y chart
Events in this range
- Nov 19, 2021Dividend: 0.28
- Feb 25, 2022Dividend: 0.28
- May 13, 2022Dividend: 0.28
- Aug 12, 2022Dividend: 0.28
- Nov 10, 2022Dividend: 0.28
- Dec 15, 2022Dividend: 0.28
- Feb 24, 2023Dividend: 0.28
- May 12, 2023Dividend: 0.28
- Aug 17, 2023Dividend: 0.28
- Nov 9, 2023Dividend: 0.28
- Nov 10, 2023Dividend: 0.28
- Feb 23, 2024Dividend: 0.28
- May 10, 2024Dividend: 0.28
- Aug 16, 2024Dividend: 0.28
- Nov 12, 2024Dividend: 0.28
- Feb 24, 2025Dividend: 0.28
- May 12, 2025Dividend: 0.02
- Aug 15, 2025Dividend: 0.02
- Nov 10, 2025Earnings: 1.01; estimate 0.93; surprise 8.6%
- Nov 11, 2025Rating: Morgan Stanley · Equal-Weight → Equal-Weight
- Nov 11, 2025Rating: JP Morgan · Underweight → Underweight
- Nov 20, 2025Dividend: 0.02
- Dec 9, 2025Rating: Barclays · — → Underweight
- Feb 12, 2026Earnings: 0.63; estimate 0.73; surprise -13.7%
- Feb 23, 2026Dividend: 0.02
- Feb 24, 2026Rating: Barclays · Underweight → Underweight
- Apr 28, 2026Rating: Piper Sandler · Underweight → Neutral
- Apr 29, 2026Downgrade: BNP Paribas · Outperform → Neutral
- Apr 30, 2026Earnings: 0.71; estimate 0.83; surprise -14.46%
- May 11, 2026Dividend: 0.02
- Jul 31, 2026Earnings: 0.85; estimate 0.85; surprise 0%
- Aug 14, 2026Dividend: 0.02
- Oct 30, 2026Earnings: 0.94; estimate 0.88; surprise 6.82%
Signals (77)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 26, 2026 | 1 week ago |
| MACD: Sell Signal | Aug 3, 2026 | 3 months ago |
| RSI: Overbought | Apr 27, 2026 | 6 months ago |
| SMA: Bullish | Apr 6, 2026 | 7 months ago |
| SMA: Bullish | Apr 6, 2026 | 7 months ago |
| MACD: Buy Signal | Apr 6, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 9, 2026 | 7 months ago |
| SMA: Bearish | Feb 23, 2026 | 8 months ago |
| SMA: Bullish | Feb 16, 2026 | 8 months ago |
| SMA: Bearish | Feb 9, 2026 | 8 months ago |
| SMA: Bearish | Jan 26, 2026 | 9 months ago |
| SMA: Bullish | Jan 19, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 5, 2026 | 10 months ago |
| SMA: Bullish | Dec 29, 2025 | 10 months ago |
| MACD: Sell Signal | Oct 27, 2025 | 1 year ago |
| RSI: Oversold | Oct 27, 2025 | 1 year ago |
| SMA: Bearish | Oct 6, 2025 | 1 year ago |
| SMA: Bearish | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Sep 29, 2025 | 1 year ago |
| SMA: Bullish | Sep 1, 2025 | 1 year ago |
| SMA: Bearish | Jul 28, 2025 | 1 year ago |
| SMA: Bullish | Jul 21, 2025 | 1 year ago |
| SMA: Bearish | Jul 14, 2025 | 1 year ago |
| SMA: Bullish | Jun 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 23, 2025 | 1 year ago |
| SMA: Bearish | Jun 16, 2025 | 1 year ago |
| SMA: Bullish | Jun 9, 2025 | 1 year ago |
| RSI: Oversold | Apr 28, 2025 | 1 year ago |
| RSI: Oversold | Apr 7, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 31, 2025 | 1 year ago |
| SMA: Bearish | Mar 24, 2025 | 1 year ago |
| SMA: Bullish | Mar 17, 2025 | 1 year ago |
| SMA: Bearish | Mar 10, 2025 | 1 year ago |
| SMA: Bullish | Mar 3, 2025 | 1 year ago |
| SMA: Bearish | Feb 24, 2025 | 1 year ago |
| SMA: Bullish | Feb 17, 2025 | 1 year ago |
| SMA: Bearish | Feb 3, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 20, 2025 | 1 year ago |
| SMA: Bullish | Jan 6, 2025 | 1 year ago |
| SMA: Bearish | Sep 16, 2024 | 2 years ago |
| SMA: Bearish | Sep 2, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 2, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 26, 2024 | 2 years ago |
| SMA: Bullish | Aug 19, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 5, 2024 | 2 years ago |
| SMA: Bearish | Jul 29, 2024 | 2 years ago |
| SMA: Bullish | Jul 8, 2024 | 2 years ago |
| SMA: Bearish | Jul 1, 2024 | 2 years ago |
| SMA: Bullish | Apr 22, 2024 | 2 years ago |
| SMA: Bearish | Apr 1, 2024 | 2 years ago |
| SMA: Bullish | Feb 12, 2024 | 2 years ago |
| MACD: Buy Signal | Dec 25, 2023 | 2 years ago |
| SMA: Bullish | Dec 18, 2023 | 2 years ago |
| RSI: Oversold | Oct 23, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 18, 2023 | 3 years ago |
| SMA: Bearish | Sep 4, 2023 | 3 years ago |
| SMA: Bullish | Jul 10, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 10, 2023 | 3 years ago |
| SMA: Bearish | May 1, 2023 | 3 years ago |
| SMA: Bullish | Apr 17, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 27, 2023 | 3 years ago |
| SMA: Bearish | Feb 13, 2023 | 3 years ago |
| SMA: Bearish | Feb 6, 2023 | 3 years ago |
| SMA: Bullish | Jan 2, 2023 | 3 years ago |
| MACD: Buy Signal | Nov 28, 2022 | 3 years ago |
| SMA: Bullish | Nov 21, 2022 | 3 years ago |
| RSI: Oversold | Sep 19, 2022 | 4 years ago |
| SMA: Bearish | Jul 4, 2022 | 4 years ago |
| SMA: Bearish | Jun 27, 2022 | 4 years ago |
| SMA: Bullish | Jun 20, 2022 | 4 years ago |
| SMA: Bullish | Jun 20, 2022 | 4 years ago |
| SMA: Bearish | Jun 13, 2022 | 4 years ago |
| SMA: Bearish | Jun 13, 2022 | 4 years ago |
| SMA: Bullish | May 9, 2022 | 4 years ago |
| SMA: Bearish | Apr 11, 2022 | 4 years ago |
| SMA: Bullish | Apr 4, 2022 | 4 years ago |
| SMA: Bearish | Mar 28, 2022 | 4 years ago |
Key statistics
- Market cap
- 3.63B
- Enterprise value
- 11.05B
- Trailing P/E
- 17.74
- Forward P/E
- 3.79
- PEG ratio
- 0.00
- Price / sales
- 0.59
- Price / book
- 3.61
- EPS (TTM)
- 0.78
- Beta
- 1.54
- Dividend yield
- 0.58%
- Payout ratio
- 10.26%
- Profit margin
- 3.41%
- Revenue (TTM)
- 6.13B
- Revenue growth
- -2.30%
- Free cash flow
- 490.75M
- Total cash
- 1.13B
- Total debt
- 8.55B
- Return on equity
- 24.04%
- Shares outstanding
- 262.61M
- Short % of float
- 8.15%
- 50-day average
- 13.74
- 200-day average
- 11.49
Analyst view
Consensus: hold
- Target (low)
- 8.00
- Target (mean)
- 10.33
- Target (high)
- 14.00
- Strong buy0
- Buy0
- Hold3
- Sell0
- Strong sell1
Next earnings
Feb 11, 2027
Expected Feb 11, 2027. Consensus EPS estimate 0.94645.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2027 | Dec 30, 2026 | 0.92 | — | — | — |
| Oct 30, 2026 | Sep 30, 2026 | 0.88 | 0.94 | +0.06 | +6.82% |
| Jul 31, 2026 | Jun 30, 2026 | 0.85 | 0.85 | 0.00 | 0.00% |
| Apr 30, 2026 | Mar 31, 2026 | 0.83 | 0.71 | -0.12 | -14.46% |
| Feb 12, 2026 | Dec 31, 2025 | 0.73 | 0.63 | -0.10 | -13.70% |
| Nov 10, 2025 | Sep 30, 2025 | 0.93 | 1.01 | +0.08 | +8.60% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 29, 2026 | BNP Paribas | down | Outperform | Neutral |
| Apr 28, 2026 | Piper Sandler | up | Underweight | Neutral |
| Feb 24, 2026 | Barclays | main | Underweight | Underweight |
| Dec 9, 2025 | Barclays | init | — | Underweight |
| Nov 11, 2025 | JP Morgan | main | Underweight | Underweight |
| Nov 11, 2025 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
About Organon & Co.
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Website
- organon.com
News
- Organon (OGN) Q3 Earnings and Revenues Top Estimates
- Organon Announces Quarterly Dividend
- Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
- Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
- Organon & Co. (NYSE:OGN) & Xeris Biopharma (NASDAQ:XERS) Critical Comparison
- Organon To Present Data From Its Current Phase 3 Trial Of MIUDELLA Intrauterine Device At 2026 Society Of Family Planning Annual Meeting
- Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting
- Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
- Orogen Royalties Enters into Agreement to Sell the Slaughterhouse Copper-Gold Project to Seabridge Gold
- Orogen Royalties Creates a Royalty on the Cibola Copper-Gold Project in British Columbia
Your note
Sign in to keep a note on OGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALI KEVIN | Chief Executive Officer | Purchase | May 4, 2025 | 282,731 |
| COX CARRIE SMITH | Officer and Director | Purchase | Nov 11, 2025 | 0 |
| FALCIONE AARON | Officer | Conversion of Exercise of derivative security | Mar 30, 2026 | 101,431 |
| HOLZBAUR LYNETTE | Officer | Purchase | May 5, 2026 | 52,850 |
| KARP DANIEL | Officer | Conversion of Exercise of derivative security | Mar 30, 2026 | 69,547 |
| MORRISSEY JOSEPH T JR | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 30, 2026 | 123,123 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 12.21% | 32,056,866 | 443.67M | Jun 29, 2026 |
| Pentwater Capital Management Lp | 6.89% | 18,100,000 | 250.50M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.76% | 15,132,118 | 209.43M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.54% | 11,909,865 | 164.83M | Jun 29, 2026 |
| State Street Corporation | 3.68% | 9,659,371 | 133.69M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 1.98% | 5,199,002 | 71.95M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.95% | 15,638,261 | 216.43M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 8,332,789 | 115.33M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.29% | 6,024,699 | 83.38M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 1.45% | 3,815,001 | 52.80M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.15% | 3,010,255 | 41.66M | Jun 29, 2026 |
| NexPoint Funds I-NexPoint Merger Arbitrage Fund | 1.03% | 2,705,080 | 37.44M | Jun 29, 2026 |